



May 13, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Outcome of Board Meeting
Ref: Regulation 30 and 33 of SEBI (LODR)
Regulations, 2015 ('SEBI Listing Regulations')

We wish to inform you that Board of Directors of the Company at their Meeting held on **Monday, May 13, 2024**, inter-alia considered and approved the following:

- A.** The Audited Financial Results and Statements of the Company (Standalone and Consolidated) for the Quarter and Year ended March 31, 2024, based on the recommendation of the Audit Committee.

In this regards we enclose;

1. Audited Financial Results and Statements;
2. Statement of Assets and Liabilities;
3. Cash Flow Statement;
4. Auditor's Report on the Financial Results & Statements;
5. Declaration in respect of Audit Reports with unmodified opinion for the year ended March 31, 2024.

- B.** Recommendation of the Final Dividend of Re. 1/- (20%) (Rupee One only) per Equity Share of Face Value of Rs. 5/- each for the Financial Year ended March 31, 2024, subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company.

- C.** Appointment of Shri Pradeep Thakur (DIN: 00685992) as a Non-Executive Independent Director for a term of 5 (five) years with effect from May 13, 2024 up to May 12, 2029 based on recommendation of Nomination and Remuneration Committee and subject to the approval of Members of the Company. The required details pursuant to SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith in **Annexure - I**.

Further, in terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, we have received confirmation from Shri Pradeep Thakur, that he is not debarred from accessing capital markets and/ or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority.

- D.** Appointment of Smt. Nehal Garewal (DIN: 01750146) as a Non-Executive Non-Independent Director with effect from May 13, 2024 based on recommendation of Nomination and

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@artipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



Remuneration Committee and subject to the approval of Members of the Company. The required details pursuant to SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith in **Annexure - I.**

- E. Appointment of Smt. Ketki D. Visariya, Cost Accountant (Membership No. 16028), as the Cost Auditor of the Company for FY 2024–25. The required details pursuant to Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith in **Annexure-II.**
- F. Appointment of Shri Sunil M. Dedhia, Practising Company Secretary (Membership No. F3483 and Certificate of Practice No. 2031), as the Secretarial Auditor of the Company for FY 2024–25. The required details pursuant to Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith in **Annexure-II.**
- G. Appointment of Manish Modi & Associates, Chartered Accountant (Firm Registration No. 120780W), as the Internal Auditor of the Company for FY 2024–25. The required details pursuant to Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith in **Annexure-II.**

The meeting of the Board of Directors commenced at 12:00 noon and concluded at 05:15 p.m.

Further, please note that the Company has already made necessary arrangement to publish the financial results in the Newspapers as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is also available on the website of the Company: www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

Encl: a/a

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@artipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Annexure-I

Brief details of Directors seeking appointment, as required under Regulation 30 of the SEBI Listing Regulations

Sr. No.	Particulars	Details of the Directors	
1	Name and DIN	Shri Pradeep Thakur (DIN: 00685992)	Smt. Nehal Garewal (DIN: 01750146)
2	Date of Appointment	May 13, 2024	May 13, 2024
3	Reason for change viz. appointment	<p>The Company seeks to benefit from the expert advice and rich experience of Shri Pradeep Thakur (DIN: 00685992). Besides, it is expected that he can help strengthen the governance framework and influence the Board culture of the Company.</p> <p>Hence, in compliance with the provisions of Sections 149, 150 and 152 and other applicable provisions of the Companies Act, 2013 ("Act") and SEBI Listing Regulations and on the recommendation of the Nomination and Remuneration Committee (NRC) and subject to the approval of shareholders, the Board of Directors in its meeting held on May 13, 2024 approved the appointment of Shri Pradeep Thakur as a Non-Executive Independent Director of the Company for the first term of 5 (Five) Years, effective from May 13, 2024.</p>	<p>Smt. Nehal Garewal (DIN: 01750146) is closely associated with the growth of the company as the Promoter Group shareholder. Besides, she had earlier worked in various capacities at Aarti Industries Limited, whose pharma undertaking was demerged and transferred to Aarti Pharmalabs Limited in the year 2021.</p> <p>Hence, in compliance with the provisions of Sections 149 and 152 and other applicable provisions of the Companies Act, 2013 ("Act") and SEBI Listing Regulations and on the recommendation of the Nomination and Remuneration Committee (NRC) and subject to the approval of shareholders, the Board of Directors in its meeting held on May 13, 2024 approved the appointment of Smt. Nehal Garewal as a Non-Executive Non-Independent Director of the Company effective from May 13, 2024.</p>
4	Term of Appointment	5 (five) years	N.A.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

5	Brief Profile	<p>Shri Pradeep Thakur is a Post Graduate in Chemistry from Mumbai University and has a Diploma in Export Management. Besides, he has studied 'Masters in Administrative Management' at Jamnalal Bajaj Institute of Management Studies, Mumbai.</p> <p>Shri Thakur possesses more than 30 years of working experience in Chemical and Pharmaceutical Industry in various functions like Process Development, Quality control, Quality Assurance, Business Development and General Administration. He was the Managing Director of Aceto Pharma India Private Limited. Shri Thakur is member of the Board of Directors of Indo Amines Limited and Anuh Pharma Limited.</p>	<p>Smt. Nehal Garewal is Commerce Graduate from Mumbai University and holds Diploma in Financial Management from NMIMS, Mumbai.</p> <p>She is an accomplished Director with over 30 years of work experience. She has worked in the Manufacturing, Social & Education and in Security Safety and Risk Management industries gaining extensive knowledge of commercial strategy, planning, execution and innovation. She can leverage her capabilities and leadership skills to assist organizations with their growth and development.</p>
6	Disclosure of relationships between Directors (in case of appointment of a director)	No relationship exists with any other Directors/KMP.	No relationship exists with any other Directors/KMP.

Yours faithfully,
For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
 ICSI M. NO. A27738

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
 Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Annexure-II

Brief details of Auditors seeking appointment, as required under Regulation 30 of the SEBI Listing Regulations

Sr. No.	Particulars	Disclosure		
		Cost Auditor	Secretarial Auditor	Internal Auditor
1	Reason for change	Appointment of Smt. Ketki D. Visariya, Cost Accountant (Membership Number 16028), as the Cost Auditor of the Company for FY 2024-25.	Appointment of Shri Sunil M. Dedhia, Practising Company Secretary (Membership No. F3483 and Certificate of Practice No.2031), as the Secretarial Auditor of the Company for FY 2024-25.	Appointment of Manish Modi & Associates, Chartered Accountant as the Internal Auditor of the Company for FY 2024-25.
2	Date and term of Appointment	Smt. Ketki D. Visariya, Cost Accountant appointed as the Cost Auditor on May 13, 2024 for a term of 1 (one) year for FY 2024-25.	Shri Sunil M. Dedhia, Practising Company Secretary appointed as the Secretarial Auditor on May 13, 2024 for a term of 1 (one) year for FY 2024-25.	Manish Modi & Associates, Chartered Accountant appointed as the Internal Auditor on May 13, 2024 for a term of 1 (one) year for FY 2024-25.
3	Brief Profile	CMA Ketki D. Visariya has vast exposure and experience serving various companies as a Cost Consultant for the past 29 years. Presently she is cost auditor for various companies and consulting for CAS-IV certification. Smt. Viseria specialises in the Cost Audit of Chemical, Textiles, Paper, Electricity, Engineering, Bulk Drugs, Fertilizers, Gems & Jewellery, Garments, Automobiles, Food, Cosmetics & Toiletries, Printing & Publishing, Paint Industry, Telecommunication	Sunil M. Dedhia & Co., is Practising Company Secretary proprietary concern founded by CS Shri Sunil M. Dedhia. He is Commerce Graduate from Mumbai University, qualified as Chartered Accountant (A.C.A.) and fellow Company Secretary (F.C.S.). Shri Dedhia is engaged in the profession of corporate laws advisory and consultancy since October, 1993 to listed and unlisted Companies and Corporate Groups. His core areas of practice are handling of Company Law Secretarial matters, advisory on merger/	Manish Modi and Associates is an intermix of young and qualified professionals (CA/CS/LLB) providing research based solutions in a plethora of fields such as Auditing and Assurance, International Taxation, Business consultancy Services, Legal Compliances, Project Financing, Mergers and Acquisitions, Valuations, IPO Advisory and so on.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
 Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



		etc.	demerger/joint venture/capital restructuring assignments, Secretarial Audit, Compliance Certificate services and FEMA related certifications.	
--	--	------	---	--

Yours faithfully,
For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

AARTI PHARMALABS LIMITED



www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED
 Standalone Audited Financial Results for the Quarter & Year ended 31st March, 2024

(Rs in Lakhs except EPS)

Sr. No.	Particulars	Standalone Results				
		3 Months Ended			Year Ended	
		31st Mar 2024 (Audited)	31st Dec 2023 (Audited)	31st Mar 2023 (Audited)	31st Mar 2024 (Audited)	31st Mar 2023 (Audited)
1	INCOME					
	a) Revenue from Operations (Net)	41,482	37,303	37,427	150,213	151,125
	b) Other Income	569	46	0	1,101	128
	Total Income	42,050	37,349	37,427	151,314	151,253
2	EXPENSES					
	a) Cost of Materials Consumed	17,969	19,111	21,012	76,157	89,945
	b) Purchases of Stock-in-Trade	0	0	0	1,376	970
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	736	-532	-870	-2,336	-9,122
	d) Employee Benefits Expense	3,467	3,429	3,094	13,033	12,216
	e) Finance Costs	442	436	580	1,663	2,049
	f) Depreciation and Amortisation Expenses	1,732	1,694	1,425	6,601	5,577
	g) Other Expenses	8,575	6,468	6,511	27,367	26,283
	Total Expenses	32,922	30,605	31,752	123,862	127,917
3	Profit/(Loss) before Exceptional Items and Tax (1-2)	9,128	6,744	5,674	27,452	23,336
4	Exceptional Items					
5	Profit/(Loss) before Tax (3-4)	9,128	6,744	5,674	27,452	23,336
6	TAX EXPENSES*					
	a) Current Year Tax	1,476	1,300	1,400	4,912	4,900
	b) Earlier Year Tax	-306	0	0	-306	313
	c) Deferred Tax	1,657	625	275	2,782	950
	Total Tax Expenses	2,826	1,925	1,675	7,387	6,163
7	Net Profit/(Loss) from Ordinary Activities after Tax (5-6)	6,302	4,819	3,999	20,065	17,173
8	Exceptional Items					
9	Net Profit/(loss) for the period (7-8)	6,302	4,819	3,999	20,065	17,173
10	OTHER COMPREHENSIVE INCOME					
	a. Items that will be reclassified to Statement of Profit and Loss	-111	70	-63	13	-70
	b. Items that will Not be reclassified to Statement of Profit and Loss					
11	Total Comprehensive Income for the period (10+11)	6,191	4,889	3,937	20,078	17,103
12	Earnings per Equity share: -(Rs)					
	(1) Basic	6.95	5.32	4.41	22.14	18.95
	(2) Diluted	6.95	5.32	4.41	22.14	18.95
13	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531	4,531	4,531	4,531	4,531
14	Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year				157,615	139,326
<p>1 The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).</p> <p>2 The above results for the quarter ended and year ended March 2024, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 13th May, 2024.</p> <p>3 The Company has identified only one segment i.e. Pharmaceuticals</p> <p>4 The Board of Directors has recommended a dividend of Rs. 1.00/- (20%) per equity share of Rs 5/- each for the financial year ended March 31, 2024</p> <p>5 The aforesaid financial results are available on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com</p>						
Place : Mumbai Date : 13th May 2024				For AARTI PHARMALABS LIMITED  Hetal Gogri Gala Vice Chairperson & Managing Director		

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@artipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED

Consolidated Audited Financial Results for the Quarter & Year Ended 31st March, 2024

(Rs in Lakhs except EPS)

Sr. No.	Particulars	Consolidated Results				
		3 Months Ended			Year Ended	
		31st Mar 2024 (Audited)	31st Dec 2023 (Audited)	31st Mar 2023 (Audited)	31st Mar 2024 (Audited)	31st Mar 2023 (Audited)
1	INCOME					
	a) Revenue from Operations (Net)	50,577	44,869	48,506	185,261	194,523
	b) Other Income	203	139	74	490	232
	Total Income	50,780	45,008	48,580	185,750	194,755
2	EXPENSES					
	a) Cost of Materials Consumed	20,152	21,496	22,699	85,845	101,430
	b) Purchases of Stock-in-Trade	5,991	3,846	7,468	18,222	28,082
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	-831	-899	-667	-1,995	-12,536
	d) Employee Benefits Expense	3,740	3,616	3,323	13,841	12,969
	e) Finance Costs	468	448	594	1,721	2,105
	f) Depreciation and Amortisation Expenses	1,912	1,877	1,595	7,324	6,254
	g) Other Expenses	9,773	7,243	7,685	30,744	30,374
	Total Expenses	41,205	37,626	42,696	155,701	168,678
3	Profit/(Loss) before Exceptional Items and Tax (1-2)	9,575	7,382	5,884	30,049	26,077
4	Exceptional Items					
5	Profit/(Loss) before Tax (3-4)	9,575	7,382	5,884	30,049	26,077
6	TAX EXPENSES*					
	a) Current Year Tax	1,693	1,437	1,424	5,884	5,599
	b) Earlier Year Tax	-306	0	0	-306	313
	c) Deferred Tax	1,663	669	174	2,782	817
	Total Tax Expenses	3,050	2,106	1,597	8,359	6,729
7	Net Profit/(Loss) from Ordinary Activities after Tax (5-6)	6,525	5,276	4,287	21,690	19,349
8	Exceptional Items (Net of Tax Expense)					
9	Net Profit/(loss) for the period (7-8)	6,525	5,276	4,287	21,690	19,349
10	Profit/(loss) for the period attributable to					
	a) Owners of the Company	6,525	5,276	4,287	21,690	19,349
	b) Non Controlling Interest	0	0	0		
11	OTHER COMPREHENSIVE INCOME					
	a. Items that will be reclassified to Statement of Profit and Loss	-89	29	-505	-45	-345
	b. Items that will Not be reclassified to Statement of Profit and Loss					
12	Total Comprehensive Income for the period (10+11)	6,436	5,306	3,782	21,645	19,004
13	Earnings per Equity share: - (Rs)					
	(1) Basic	7.20	5.82	4.73	23.93	21.35
	(2) Diluted	7.20	5.82	4.73	23.93	21.35
14	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531	4,531	4,531	4,531	4,531
15	Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year				171,173	151,317

 Place : Mumbai
 Date : 13th May 2024


For AARTI PHARMALABS LIMITED


 Hetal Gogri Gala
 Vice Chairperson & Managing Director

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED					
Standalone and Consolidated Balance Sheet as at 31st March, 2024					
(Rs in Lakhs)					
Sr. No.	Particulars	Standalone		Consolidated	
		As at 31st March 2024	As at 31st March 2023	As at 31st March 2024	As at 31st March 2023
A	ASSETS				
1	Non-Current Assets				
	(a) Property, Plant and Equipment	91,600	84,708	99,422	92,274
	(b) Capital work-in-progress	7,850	6,223	7,850	6,220
	(C) Right to use Assets	2,047	114	2,047	114
	(d) Goodwill	0	0	178	178
	(e) Other Intangible assets	1,686	18	1,685	18
	(f) Intangible assets under Development	5,842	3,967	5,842	3,967
	(g) Financial Assets				
	(i) Investments				
	(a) Investment in Subsidiary & Joint Control	1,352	1,352	0	0
	(b) Investments (Others)	3,032	2,916	3,678	3,552
	(c) Loan	585	585	585	585
	(ii) Other Financial Assets	1,066	883	1,133	944
	(h) Other Non-Current Assets	1,226	249	1,226	249
	Total Non-Current Assets	116,285	101,015	123,646	108,102
2	Current Assets				
	(a) Inventories	58,215	53,768	64,286	60,204
	(b) Financial Assets				
	(i) Investments	1,783	1,281	7,039	5,099
	(j) Trade Receivables	44,882	37,167	51,934	45,010
	(ii) Cash and Cash Equivalents	400	30	2,363	1,212
	(iii) Bank Balance Other than (ii) above	43	7	43	7
	(iv) Loans	93	101	125	125
	(v) Other Current Financial Assets	628	507	628	509
	(c) Other Current Assets	7,057	3,762	7,800	4,134
	Current Tax Assets (Net)	305	0	344	0
	Total Current Assets	113,406	96,622	134,564	116,301
	TOTAL ASSETS	229,691	197,637	258,210	224,402
B	EQUITY AND LIABILITIES				
1	Equity				
	(a) Equity Share Capital	4,531	4,531	4,531	4,531
	(b) Other Equity	157,615	139,326	171,173	151,317
	(c) Non Controlling Interest	0	0	0	0
	Total Equity	162,146	143,858	175,704	155,849
2	Liabilities				
	Non-Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	0	0	4	18
	(i) Lease Liabilities	1,666	53	1,666	53
	(ii) Provisions	528	466	606	536
	(b) Deferred Tax Liabilities (Net)	9,793	6,885	10,792	7,884
	Total Non-Current Liabilities	11,987	7,404	13,068	8,491
	Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	25,080	20,671	26,406	21,415
	(ii) Lease Liabilities	449	44	449	44
	(iii) Trade Payables due to				
	- Micro and Small Enterprises	1,890	1,265	1,890	1,265
	- Other Than Micro and Small Enterprises	23,588	19,984	35,942	32,685
	(iii) Others Financial Liabilities	2,842	2,307	3,020	2,471
	(b) Provisions	624	544	631	550
	(c) Current Tax Liabilities (Net)	0	290	0	352
	(d) Other Current Liabilities	1,084	1,269	1,100	1,280
	Total Current Liabilities	55,558	46,375	69,439	60,062
	TOTAL EQUITY AND LIABILITIES	229,691	197,637	258,210	224,402



For AARTI PHARMALABS LIMITED

Hetal Gogri Gala
Vice Chairperson & Managing Director

Place : Mumbai
Date : 13th May 2024

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED					
Cash Flow Statement for the Year Ended 31st March, 2024				(Rs in Lakhs)	
Sr. No.	Particulars	Standalone		Consolidated	
		For the Year Ended 31st March 2024	For the Year Ended 31st March 2023	For the Year Ended 31st March 2024	For the Year Ended 31st March 2023
A.	Cash Flow from Operating Activities:				
	Net Profit before Tax and Exceptional/Extraordinary Items	27,452	23,336	30,049	26,077
	<u>Adjustments for:</u>				
	Finance Costs	1,663	2,049	1,721	2,105
	Depreciation and Amortisation Expenses	6,601	5,577	7,324	6,254
	Dividend Income	-929	-128	-3	-125
	Interest income	-47	0	-304	-94
	Profit on Sale of Assets/Investments	0	39	-55	45
	R&D Project write off	676	0	676	0
	Provision for Bad and Doubtful Debts	107	150	107	150
	Consolidated Adjustment	0	0	0	0
	Operating Profit before Working Capital Changes	35,523	31,023	39,514	34,413
	<u>Adjustments for:</u>				
	(Increase)/Decrease in Trade and Other Receivables	-12,439	-3,615	-12,554	-3,517
	(Increase)/Decrease in Inventories	-4,447	-9,330	-3,966	-12,666
	Increase/(Decrease) in Trade Payables and Other Current Liabilities	4,432	9,184	4,335	13,020
	Cash Generated from Operations	23,069	27,261	27,329	31,250
	Direct Taxes Paid	-4,699	-5,673	-5,694	-6,238
	Net Cash Flow from Operating Activities (A)	18,370	21,588	21,636	25,012
B.	Cash Flow from Investing Activities:				
	Addition to Property, Plant & Equipment/Capital WIP	-14,596	-9,892	-15,560	-10,213
	Investments under Intangible assets under Development	-4,318	-1,753	-4,318	-1,753
	(Increase)/Decrease in Other Investments	-502	0	-1,940	-3,868
	Dividend Income	929	128	3	4
	Interest income	47	0	304	94
	Profit on Sale of Assets/Investments	0	-39	55	-45
	Net Cash Flow from Investing Activities (B)	-18,441	-11,555	-21,457	-15,780
C.	Cash Flow from Financing Activities:				
	Proceeds/(Repayment) of Borrowings	4,408	-11,791	4,999	-12,429
	Finance Costs	-1,663	-2,049	-1,721	-2,105
	Lease liability payment	-493	0	-493	0
	Dividend Paid	-1,813	-1,813	-1,813	-1,813
	Net Cash Flow from Financing Activities (C)	440	-15,653	972	-16,346
	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	370	-5,620	1,151	-7,115
	Cash and Cash Equivalents (Opening Balance)	30	5,650	1,212	8,327
	Cash and Cash Equivalents (Closing Balance)	400	30	2,363	1,212



Place : Mumbai
 Date : 13th May 2024

For AARTI PHARMALABS LIMITED

Hetal Gogri Gala
 Vice Chairperson & Managing Director

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



Independent Auditors' Report on Audit of Standalone Financial Results

To Board of Directors of
Aarti Pharmalabs Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Aarti Pharmalabs Limited ('the Company') for the quarter and year ended 31 March 2024 ('standalone financial results') attached herewith, being submitted by the Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') and other accounting principles generally accepted in India of the net profit and total other comprehensive income, and other financial information of the Company for the quarter and year ended 31 March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the standalone financial statements.

The Company's Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards under Section 133 of the Act read with rules mentioned thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design,





implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of





the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN:- 24123215BKBNZF9774
Place: Mumbai
Date: 13 May 2024





Independent Auditors' Report on Audit of Consolidated Financial Results

To Board of Directors of Aarti Pharamalabs Limited
Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Pharamalabs Limited ('Holding Company'), its subsidiaries and jointly controlled entity (Holding Company together with its subsidiaries and jointly controlled entity 'the Group') for the quarter and year ended 31 March 2024 ('Consolidated financial results'), being submitted by the Holding Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements / financial information of subsidiaries and jointly controlled entity (refer other matter paras), the Statement:

1. includes the results of the following entities:
 - a. **Subsidiaries**
 - i. Aarti USA Inc
 - ii. Aarti Pharmachem Limited
 - b. **Jointly Controlled Entity**
 - i. Ganesh Polychem Limited
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the Consolidated net profit and Consolidated total other comprehensive income and other financial information of the Group for the quarter and year ended 31 March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.





Management's Responsibilities for the Consolidated Financial Results.

These Consolidated Financial Results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's Internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the Financial Results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in the section titled 'Other Matters' in this audit report.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





I. Financial Results of Subsidiaries not audited by us.

- a) The consolidated financial results include the audited financial results of 1 subsidiary and 1 Jointly controlled entity whose financial results, considered in the consolidated financial statements, reflect total assets of Rs. 18493 lakhs (before consolidation adjustments) as at 31 March 2024, total revenues of Rs. 4231 lakhs and Rs. 16939 lakhs (before consolidation adjustments) and total net profit after tax of Rs. 563 lakhs and Rs. 2399 lakhs (before consolidation adjustments) for the quarter and year ended 31 March 2024 and cash outflows (net) of Rs. 302 lakhs (before consolidation adjustments) for the year ended 31 March 2024 respectively as considered in the consolidated financial results, which have been audited by their respective independent auditors. The independent auditors' reports on financial results of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- b) The consolidated financial results include the audited financial results of 1 foreign subsidiary whose financial results/ financial information reflects total assets of Rs. 11612 lakhs (before consolidation adjustments) as at 31 March 2024, total revenues of Rs. 4789 lakhs and Rs. 18819 lakhs (before consolidation adjustments) and total net profit after tax of Rs. 131 lakhs and Rs.119 lakhs (before consolidation adjustments) for the quarter and year ended 31 March 2024 and cash inflows (net) of Rs. 1084 lakhs (before consolidation adjustments) for the year ended 31 March 2024 respectively as considered in the consolidated financial results. These audited financial statements have been furnished to us by the board of directors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such audited financial statements.

Our opinion is not modified in respect of the above matter.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN: 24123215BKBNZG2870
Date: 13 May 2024
Place: Mumbai





May 13, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

**Sub: Declaration in respect of Audit Reports with un-modified
opinion for the Financial Year ended March 31, 2024.
Ref: Regulation 33 of SEBI (LODR) Regulations, 2015**

We hereby confirm and declare that the Statutory Auditors of the Company, Gokhale & Sathe, Chartered Accountants (Firm Registration No.: 103264W) have issued the Audit Report with un-modified opinion in respect of Annual Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2024.

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655